Trial · NCT07207057
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
NCT07207057, Phase 3, Recruiting, University College, London
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial. Trials, record NCT07207057. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07207057
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
- NCT number
- NCT07207057
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,200 participants, estimated
- Lead sponsor
- University College, London
- Conditions
- Parkinsons Disease (PD)
- Interventions
- Placebo, Telmisartan, Terazosin (Hytrin)
- First posted
- 2025-10-03
- Last updated
- 2025-10-03
- Other registries' IDs
- isrctn:ISRCTN17799294
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I and II combined | baseline, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination and week 165 | The rate of Parkinson's disease progression between the active treatment and placebo arms is measured by the MDS-UPDRS Parts I and II combined with equal weighting |
| Secondary | Hoehn and Yahr Scale (H&Y) | screening, week 0, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination and week 165 | Clinician reported measures. Parkinson's disease stage is measured using the Hoehn and Yahr Scale (H\&Y) |
| Secondary | Montreal Cognitive Assessment (MoCA) | screening, week 0, week 26, week 52, week 104, week 156 or early termination. | Clinician reported measures. Cognitive impairment is measured using the Montreal Cognitive Assessment (MoCA) |
| Secondary | levodopa-equivalent daily dose (LEDD) | all study visits | Clinician reported measures. Parkinson's disease medication use is measured by levodopa-equivalent daily dose (LEDD). |
| Secondary | Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Remote) | screening, week 0, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination and week 165. | Clinician reported measures. Part III of the MDS-UPDRS in the ON medication state (remote elements only) |
| Secondary | Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV | screening, week 0, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination and week 165 | Clinician reported measures. Part IV of the MDS-UPDRS in the ON medication state |
| Secondary | Severity of depression | screening, week 0, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination. | Participant reported measures. The severity of depression is assessed by the Patient Health Questionnaire (PHQ-9) |
| Secondary | Quality of Life - Parkinson's Disease Questionnaire (PDQ-8) | week 0, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination. | Participant reported measures. Quality of life is assessed by the Parkinson's Disease Questionnaire (PDQ-8) |
| Secondary | Carers' quality-of-life assessed by the questionnaire for parkinsonism (PQoL Carers) | week 0, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination. | Participant reported measures. Carers' quality-of-life is assessed by the questionnaire for parkinsonism (PQoL Carers) |
| Secondary | Ability to enjoy life (ICECAP-O) | week 0, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination. | Participant reported measures. Ability to enjoy life is assessed by the ICEpop CAPability measure for Older people (ICECAP-O) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07207057
GET https://conductscience.org/api/trials/v1/NCT07207057/registered